Rozlytrek - European Medicines Agency (EMA) Since Rozlytrek has been given conditional authorisation, the company that markets Rozlytrek will provide further data from ongoing studies on the effectiveness and safety of Rozlytrek in adults and children who have solid tumours with NTRK gene fusion
Rozlytrek, Roche’s first tumour-agnostic therapy, approved in Europe . . . In June 2019, Japan’s Ministry of Health, Labour and Welfare (MHLW) also approved Rozlytrek for the treatment of adult and paediatric patients with NTRK fusion-positive, advanced recurrent solid tumours, and later approved Rozlytrek in ROS1-positive NSCLC in February 2020
Rozlytrek Now Approved for Pediatric Patients Older Than 1 Month With . . . This indication for the new population was granted under the FDA’s accelerated approval process based on ORR and DOR data Continued approval for this indication for this population may be contingent on clinical benefit verification in ongoing and confirmatory studies
Rozlytrek (entrectinib) FDA Approval History - Drugs. com This indication is approved under accelerated approval based on tumor response rate and durability of response Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials
The European Medicines Agency review of entrectinib for the treatment . . . Entrectinib was granted a CMA for the treatment of patients older than 12 years with NTRK fusion-positive solid tumours A CMA was also issued for the treatment of adult patients with ROS1+ NSCLC not previously treated with ROS1 inhibitors